Latest Immutep News & Updates

See the latest news and media coverage for Immutep. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Immutep

Biotechnology company developing LAG-3 immunotherapies

immutep.com
Headquarters
Sydney, Australia
Company type
Public company
Number of employees
10–60

Latest news about Immutep

Company announcements

  • Immutep

    Immutep discontinues TACTI-004 Phase III trial

    IDMC recommends halt after futility analysis; root cause under review. IMP761 Phase I advances with favorable safety. Cash at A$110.6M extends to H1 CY2028.

  • Immutep

    Immutep receives Nasdaq bid price deficiency notice

    The Company has 180 days until October 26, 2026, to regain compliance by maintaining a US$1.00 share price for ten consecutive business days. Trading remains unaffected.

  • Immutep

    Immutep receives FDA orphan designation for eftilagimod alfa

    The designation covers eftilagimod alfa for soft tissue sarcoma and follows Phase II EFTISARC-NEO data showing median tumour hyalinization of 51.5% and favourable safety.

  • Immutep

    Immutep provides investor update post TACTI-004 discontinuation

    A root cause analysis is underway for the trial's futility. The portfolio includes assets like IMP761 with data in early June.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Immutep

Track Immutep and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.